Bio-equivalence of IR Tablet against ER Tablet [Design Issues]

posted by Jasim Uddin – Bangladesh, 2018-06-20 15:29 (2577 d 03:48 ago) – Posting: # 18929
Views: 3,530

Dear Sirs

Does anyone know about BE Study design of Immediate Release Formulation against Extended Release Formulation?

We manufacture Potassium Chloride 600 mg IR tablet. But no RLD is available as IR tablet. RLD SLOW-K 600 mg of Novartis is available as ER tablet.

Is it possible to design BE study of our IR formulation of Potassium Chloride 600 mg against SLOW-K 600 mg ER tablet?

Would appreciate kind advice of the experts in this forum.

Kind regards

Jasim

Edit: Category changed; see also this post #1. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,429 posts in 4,930 threads, 1,679 registered users;
49 visitors (0 registered, 49 guests [including 9 identified bots]).
Forum time: 19:18 CEST (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5